Is Your Organization Ready to Recapture Some of the $3 Billion Lost Each Year to Drug Wastage?

Have single-dose vials, dose, and waste, created a reimbursement challenge?

 

In RJ Health’s New White Paper “Addressing Drug Wastage: A $3 Billion Challenge” by: Todd Cooperman PharmD, MBA, R.Ph. Senior Vice President, Clinical Insights and Analytics & Manoj Kumar MBA, CPHIMS Senior Vice President, Products and Innovation

 

We examine:

  • What Drug Wastage is

  • How it occurs

  • The size and scope of the wastage challenge

  • Who it impacts

  • How it can be addressed

 

Drug wastage has significant cost ramifications to:

  • Providers – who may face audits or penalties for over-payments

  • Health Plans & Payors – where overall spend increases flow downstream and impact providers and patients

  • Patients – who absorb the increases in the overall cost of therapy and substantial premium increases

 

Readers will learn about:

  • Therapeutic classes with some multi-dose NDC options vs those with only single-does NDCs

  • Examples of average dosing, available vial size combinations and potential waste

  • Wastage percentages within select therapeutic classes

  • Average Wastage WAC per Claim of Top Specialty Drugs

  • How Drug Wastage can be Addressed and specific solutions

 

Download the white paper now: